Jason Wittes
Stock Analyst at Roth Capital
(2.61)
# 1,812
Out of 5,182 analysts
58
Total ratings
48.08%
Success rate
3.77%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $7.94 | +403.78% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $321.43 | +41.87% | 11 | May 2, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $2.24 | +614.29% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $11.92 | +84.56% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $84.49 | -14.78% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $4.49 | +144.99% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $90.74 | +26.74% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $5.26 | +109.13% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.37 | +629.93% | 1 | Jun 26, 2024 | |
| LMAT LeMaitre Vascular | Reinstates: Buy | $100 | $112.40 | -11.03% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.86 | +168.82% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.43 | +1,978.04% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $23.40 | +220.51% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $9.35 | +135.29% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $82.80 | +44.93% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $178.51 | +15.40% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $196.51 | -26.21% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7.5 | $16.10 | -53.42% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $12.12 | +1,550.17% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $34.58 | -24.81% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $7.94
Upside: +403.78%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $321.43
Upside: +41.87%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $2.24
Upside: +614.29%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $11.92
Upside: +84.56%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $84.49
Upside: -14.78%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $4.49
Upside: +144.99%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $90.74
Upside: +26.74%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $5.26
Upside: +109.13%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.37
Upside: +629.93%
LeMaitre Vascular
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $112.40
Upside: -11.03%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $1.86
Upside: +168.82%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.43
Upside: +1,978.04%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $23.40
Upside: +220.51%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $9.35
Upside: +135.29%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $82.80
Upside: +44.93%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $178.51
Upside: +15.40%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $196.51
Upside: -26.21%
Mar 3, 2022
Initiates: Buy
Price Target: $7.5
Current: $16.10
Upside: -53.42%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $12.12
Upside: +1,550.17%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $34.58
Upside: -24.81%